DE4017979A1 - Low cholesterol lipid mixt. used as medicine and for dietary nutrition - contains phosphatidyl choline, phosphatidyl ethanolamine, tri:glyceride(s), and arachidonic and docosa hexa:enoic acid - Google Patents

Low cholesterol lipid mixt. used as medicine and for dietary nutrition - contains phosphatidyl choline, phosphatidyl ethanolamine, tri:glyceride(s), and arachidonic and docosa hexa:enoic acid

Info

Publication number
DE4017979A1
DE4017979A1 DE19904017979 DE4017979A DE4017979A1 DE 4017979 A1 DE4017979 A1 DE 4017979A1 DE 19904017979 DE19904017979 DE 19904017979 DE 4017979 A DE4017979 A DE 4017979A DE 4017979 A1 DE4017979 A1 DE 4017979A1
Authority
DE
Germany
Prior art keywords
weight
low cholesterol
cholesterol
medicine
arachidonic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
DE19904017979
Other languages
German (de)
Inventor
Michael Dipl Chem Dr Schneider
Josef Pascal Zimmer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Meyer Lucas GmbH and Co
Original Assignee
Meyer Lucas GmbH and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Meyer Lucas GmbH and Co filed Critical Meyer Lucas GmbH and Co
Priority to DE19904017979 priority Critical patent/DE4017979A1/en
Publication of DE4017979A1 publication Critical patent/DE4017979A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS, COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings, cooking oils
    • A23D9/007—Other edible oils or fats, e.g. shortenings, cooking oils characterised by ingredients other than fatty acid triglycerides
    • A23D9/013—Other fatty acid esters, e.g. phosphatides

Abstract

(A) a low cholesterol lipid mixt. contains (a) ca. 15-20 wt.% phosphatidyl choline, (b) ca. 4-10 wt.% phosphatidyl ethanolamine, (c) ca. 40-80 wt.% triglycerides and (d) 2-6 wt.% of the following acids: arachidonic acid (C20:4W6) and docosahexaenoic acid (C22: 6W6). (B) a lipid mixt. contains 15-25 wt.% (a), 15-25 wt.% (b), max. 20 wt.% (c), max. 10 wt.% cholesterol and 5-10 wt.% (d). (C) another low cholesterol lipid mixt. contains at least 85 wt.% (a) and 5-10 wt.% (d). USE/ADVANTAGE - Mixts. (A), (B) and (C) can be used in medicine and dietary nutrition. The mixts. can be used to treat diseases caused by lipid coated viruses, and can influence the cell membrane of living creatures, esp. to improve the fluidity and/or permeability of the membrane for certain substances and to treat phenomena associated with unwanted changes in the cell membrane, e.g. drug and alcohol dependencies and withdrawal ageing processes etc. The presence of the unsaturated acids makes the mixts. more effective against viral infections, deficiencies of the immune system,m allergies, mental disorders, drug withdrawal symptoms, etc. The results against HIV-1 infections were found to be excellent.

Description

Die Erfindung bezieht sich auf Lipid-Zusammensetzungen und deren Einsatz auf dem medizinischen Sektor bzw. dem Bereich der diätetischen Ernährung.The invention relates to lipid compositions and their Use in the medical sector or in the field of dietary nutrition.

Es ist eine Zusammensetzung mit einer Lipidfraktion natürlicher Herkunft bekannt (EU-PS 00 74 251), die 40-80 Gew.-% Glyceride, 3-5 Gew.-% Cholesterin, 10-30 Gew.-% Lecithin (Phosphatidylcholin), 5-15 Gew.-% Phosphatidylethanolamin und 2-5 Gew.-% negativ geladene Phospholipoide enthält, wobei das Verhältnis von ungesättigten zu gesättigten Fettsäuren wenigstens 1 : 1 beträgt.It is a composition with a natural lipid fraction Origin known (EU-PS 00 74 251), the 40-80 wt .-% Glycerides, 3-5% by weight cholesterol, 10-30% by weight lecithin (Phosphatidylcholine), 5-15% by weight phosphatidylethanolamine and Contains 2-5 wt .-% negatively charged phospholipids, which Ratio of unsaturated to saturated fatty acids is at least 1: 1.

Diese Zusammensetzung hat einen weiten Einsatzbereich gefunden, und zwar immer dann, wenn es um Zellmembran bezogene Erkrankungen, Störungen, Phänomene oder Syndrome ging.This composition has found a wide range of uses, and always when it comes to cell membrane related Diseases, disorders, phenomena or syndromes went.

In der Zwischenzeit haben sich jedoch neuere Erkenntnisse der Wirkungsweise des Zellmechanismus, insbesondere im Zusammenhang mit dem Fusionsprozeß für lipidummantelte Viren und hinsichtlich der Membran-Rezeptor Interaktionen ergeben, und daher hatten sich die Erfinder die Aufgabe gestellt, eine Zusammensetzung aus Phospholipiden und anderen Bestandteilen so zu formulieren, daß noch bessere Resultate im Zusammenhang mit der Behandlung von Viruserkrankungen, Fehlfunktionen des Immunsystems, Allergien, Störungen des Geisteszustandes, Drogenentzugserscheinungen und dergleichen erzielt werden können.In the meantime, however, newer knowledge of the Mode of action of the cell mechanism, especially in connection with the fusion process for lipid-coated viruses and regarding the membrane receptor gave interactions, and therefore had the inventors set themselves the task of making up a composition Formulate phospholipids and other ingredients so that even better results related to the treatment of Viral diseases, malfunctions of the immune system, allergies,  Mental disorders, drug withdrawal symptoms and the like can be achieved.

Erreicht wird dies durch Zusammensetzungen, so wie sie in den Ansprüchen 1 bis 3 wiedergegeben sind und Applikationen, so wie sie in den Ansprüchen 4 und 5 präzisiert sind.This is achieved through compositions such as those in the Claims 1 to 3 are reproduced and applications, such as they are specified in claims 4 and 5.

Versuche mit den folgenden Zusammensetzungen haben bei der Ermittlung der HIV-1 Infizierbarkeit hervorragende Ergebnisse gebracht.Experiments with the following compositions have in the Determination of HIV-1 Infectability Excellent Results brought.

Beispiel 1example 1

Cholesterinfreie Phospholipid-Zusammensetzung mit 20 Gew.-% Phosphatidylcholin, 6 Gew.-% Phosphatidylethanolamin, 70 Gew.-% Triglyceride und mit 4 Gew.-% Arachidonsäure (C20 : 4w-6) und Docosahexaenolsäure (C22 : 6w-6).Cholesterol-free phospholipid composition with 20% by weight Phosphatidylcholine, 6% by weight phosphatidylethanolamine, 70 % By weight of triglycerides and with 4% by weight of arachidonic acid (C20: 4w-6) and docosahexaenolic acid (C22: 6w-6).

(Cholesterinfrei oder -arm im Sinne dieser Anmeldung bedeutet weniger als 0,5 Gew.-% Cholesterin).(Cholesterol free or low in the sense of this application means less than 0.5 wt% cholesterol).

Beispiel 2Example 2

Phospholipid-Zusammensetzung mit 20 Gew.-% Phosphatidylcholin, 20 Gew.-% Phosphatidylethanolamin, 5-10 Gew.-% Triglyceride, 5 Gew.-% Cholesterin und 8 Gew.-% Arachidonsäure (C20 : 4w-6) und Docosahexaenolsäure (C22 : 6w-6), sowie sonstige zuvor nicht genannte Bestandteile.Phospholipid composition with 20% by weight Phosphatidylcholine, 20% by weight phosphatidylethanolamine, 5-10% by weight triglycerides, 5% by weight cholesterol and 8% by weight Arachidonic acid (C20: 4w-6) and docosahexaenolic acid (C22: 6w-6), as well as other previously not mentioned Components.

Die Infizierbarkeit wurde in % der infizierten Zellen ermittelt, indem wie folgt vorgegangen wurde:
In Zellkulturen wurden die Zusammensetzungen nach Beispiel 1 und 2 vermischt und mit einem HIV-1 Virus inkubiert. Es wurde das Auftreten von Virus-Antigenen in den Zellen ermittelt, wobei auf die intrazellulare HIV-1-Replikation geschlossen wurde, die wiederum mit der Methode der indirekten Immunofluoreszenz mit HIV-1 Antikörpern bestimmt wurde. Entsprechend wurde mit anderen Phospholipid-Zusammensetzungen vorgegangen.Infectability was determined in% of the infected cells by doing the following:
The compositions according to Examples 1 and 2 were mixed in cell cultures and incubated with an HIV-1 virus. The occurrence of virus antigens in the cells was determined, concluding from the intracellular HIV-1 replication, which in turn was determined by the indirect immunofluorescence method with HIV-1 antibodies. The same procedure was followed with other phospholipid compositions.

Als Ergebnisse wurden für die Infizierbarkeit Werte von unter 65% nach 5 bis 6 Wochen gemessen, also Werte, die andere Phospholipid-Zusammensetzungen außerhalb des Bereichs der vorliegenden Erfindung nicht erreichen. Diese Werte liegen nämlich über 95 Gew.-%.The results for infectability were below 65% measured after 5 to 6 weeks, i.e. values that are different Phospholipid compositions outside the range of not achieve the present invention. These values lie namely over 95% by weight.

Es wurde ebenfalls überprüft, inwieweit das in den lipidbehandelten Zellen produzierte Virus infektiös ist.It was also checked to what extent this was in the virus produced by lipid-treated cells is infectious.

Hierbei wurde so vorgegangen, daß der zellfreie Überstand aus zuvor infizierten lipidbehandelten Zellkulturen separiert wurde und den gleichen, jedoch nicht infizierten, nicht lipidbehandelten Zellen zugegeben wurde. Sodann wurde, wie bereits angegeben, die intrazellulare HIV-1-Replikation ermittelt und wiederum in % der infizierten Zellen angegeben. Hierbei wurden Versuche an einer Vielzahl von Phospholipid- Zusammensetzungen gemacht und insbesondere an folgender cholesterinfreien Zusammensetzung.The procedure was such that the cell-free supernatant was removed previously infected lipid-treated cell cultures were separated and the same, but not infected, not lipid-treated cells was added. Then how previously stated intracellular HIV-1 replication determined and again in% of the infected cells. Tests on a variety of phospholipid Compositions made and in particular the following cholesterol free composition.

Beipiel 3Example 3

94 Gew.-% reines Phosphatidylcholin, 6 Gew.-% Phosphatidylethanolamin, 70 Gew.-% Triglyceride enthaltend und mit 4 Gew.-% Arachidonsäure (C20 : 4w-6) und 5 Gew.-% Docosahexaenolsäure (C22 : 6w-6).94% by weight pure phosphatidylcholine, 6% by weight Phosphatidylethanolamine, containing 70 wt .-% triglycerides and with 4% by weight arachidonic acid (C20: 4w-6) and 5% by weight Docosahexaenolic acid (C22: 6w-6).

Beim Beispiel 3 wurden im Bereich von 0 bis 6 Wochen bei Inkubation mit zellfreiem Überstand keine infizierten Zellen festgestellt, so daß geschlossen werden kann, daß Zellen, die mit einer Zusammensetzung nach Beispiel 3 behandelt worden sind und durch HIV-1 Viren infiziert worden sind, kein intaktes Virus ausschleusen, das heißt, daß der zellfreie Überstand kein infizierendes Material enthält. Example 3 was in the range of 0 to 6 weeks Incubation with cell-free supernatant, no infected cells found so that it can be concluded that cells that have been treated with a composition according to Example 3 and have been infected by HIV-1 viruses, not an intact virus discharge, which means that the cell-free supernatant is not contains infectious material.  

Vielversprechend sind Kombinationen von Zusammensetzungen, die sowohl aus Bestandteilen des Beispiels 1 oder des Beispiels 2, in Kombination mit dem Beispiel 3 bestehen.Combinations of compositions are promising both from components of example 1 or example 2, in combination with Example 3.

Claims (5)

1. Cholesterinarme Lipidmischung mit ca. 15-20 Gew.-% Phosphatidylcholin, ca. 4-10 Gew.-% Phosphatidylethanolamin, ca. 40-80 Gew.-% Triglyceriden, enthaltend 2-6 Gew.-% folgender Säuren: Arachidonsäure (C 20 : 4w6) und Docosahexaensäure (C22 : 6w-6).1.Low cholesterol lipid mixture with approx. 15-20% by weight Phosphatidylcholine, approx. 4-10% by weight Phosphatidylethanolamine, approx. 40-80% by weight triglycerides, containing 2-6% by weight of the following acids: arachidonic acid (C 20: 4w6) and docosahexaenoic acid (C22: 6w-6). 2. Lipidmischung mit ca. 15-25 Gew.-% Phosphatidylcholin, ca. 15-25 Gew.-% Phosphatidylethanlamin, maximal 20 Gew.-% Triglyceriden, maximal 10 Gew.-% Cholesterin, enthaltend 5-10 Gew.-% folgender Säuren: Arachidonsäure (C20 : 4w6) und Docosahexaensäure (C22 : 6w6).2. Lipid mixture with approx. 15-25% by weight phosphatidylcholine, approx. 15-25% by weight phosphatidylethane laminate, maximum 20% by weight Triglycerides containing a maximum of 10% by weight cholesterol 5-10% by weight of the following acids: arachidonic acid (C20: 4w6) and docosahexaenoic acid (C22: 6w6). 3. Cholesterinarme Lipidmischung mit mindestens 85 Gew.-% Phosphatidylcholin, enthaltend ca. 5-10 Gew.-% folgender Säuren: Arachidonsäure (C20 : 4w6) und Docosahexaensäure (C22 : 6w6).3. Low-cholesterol lipid mixture with at least 85% by weight Phosphatidylcholine, containing about 5-10 wt .-% of the following Acids: arachidonic acid (C20: 4w6) and docosahexaenoic acid (C22: 6w6). 4. Mittel zur Behandlung von auf lipidummantelte Viren zurückzuführende Erkrankungen, gekennzeichnet durch Verwendung von mindestens einer der Zusammensetzungen nach den Ansprüchen 1 bis 3. 4. Agents for the treatment of viruses coated with lipids diseases to be attributed, characterized by Use of at least one of the compositions according to claims 1 to 3.   5. Mittel zur Beeinflussung der Zellmembran von Lebewesen, vorzugsweise zur Verbesserung der Fluidität und/oder der Durchläßigkeit der Membrane für bestimmte Stoffe und zur Behandlung von auf unerwünschte Veränderungen der Zellmembran zurückzuführende Phänomene, wie Drogen- und Alkoholeinflüsse, Entwöhnung, Alterungsvorgänge und dergleichen, gekennzeichnet durch Verwendung mindestens einer der Zusammensetzungen nach einem der Ansprüche 1 bis 3.5. means for influencing the cell membrane of living organisms, preferably to improve fluidity and / or Permeability of the membrane for certain substances and Treatment of unwanted changes in the Phenomena due to cell membrane, such as drug and Alcohol influences, weaning, aging processes and the like, characterized by use at least one of the compositions according to any one of claims 1 to 3rd
DE19904017979 1990-06-05 1990-06-05 Low cholesterol lipid mixt. used as medicine and for dietary nutrition - contains phosphatidyl choline, phosphatidyl ethanolamine, tri:glyceride(s), and arachidonic and docosa hexa:enoic acid Ceased DE4017979A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DE19904017979 DE4017979A1 (en) 1990-06-05 1990-06-05 Low cholesterol lipid mixt. used as medicine and for dietary nutrition - contains phosphatidyl choline, phosphatidyl ethanolamine, tri:glyceride(s), and arachidonic and docosa hexa:enoic acid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19904017979 DE4017979A1 (en) 1990-06-05 1990-06-05 Low cholesterol lipid mixt. used as medicine and for dietary nutrition - contains phosphatidyl choline, phosphatidyl ethanolamine, tri:glyceride(s), and arachidonic and docosa hexa:enoic acid

Publications (1)

Publication Number Publication Date
DE4017979A1 true DE4017979A1 (en) 1991-12-12

Family

ID=6407811

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19904017979 Ceased DE4017979A1 (en) 1990-06-05 1990-06-05 Low cholesterol lipid mixt. used as medicine and for dietary nutrition - contains phosphatidyl choline, phosphatidyl ethanolamine, tri:glyceride(s), and arachidonic and docosa hexa:enoic acid

Country Status (1)

Country Link
DE (1) DE4017979A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0524796A1 (en) * 1991-07-24 1993-01-27 Scotia Holdings Plc Use of essential fatty acids in the preparation of a medicament for the treatment of AIDS
WO1994001089A1 (en) * 1992-07-08 1994-01-20 Dianorm-Geräte G. Maierhofer Liposomes, method of preparing them and their use in the preparation of drugs
EP0733360A2 (en) * 1992-11-26 1996-09-25 Scotia Holdings Plc Use of a combination of arachidonic acid and dosohexaenoic acid in the preparation of e medicament for treating cell membrane abnormalities due to low C20 or C22 essential fatty acids
EP0767666A1 (en) * 1994-08-10 1997-04-16 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
WO2004050077A1 (en) * 2002-12-05 2004-06-17 Proyecto Empresarial Brudy, S.L. Use of docosahexanoic acid as active substance for the treatment of lipodystrophy

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0074251A1 (en) * 1981-09-04 1983-03-16 Yeda Research And Development Company, Ltd. Novel lipid fraction, its preparation and pharmaceutical compositions containing same
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
WO1989003684A1 (en) * 1987-10-30 1989-05-05 Chugai Seiyaku Kabushiki Kaisha Anti-hiv agent
US4841023A (en) * 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0074251A1 (en) * 1981-09-04 1983-03-16 Yeda Research And Development Company, Ltd. Novel lipid fraction, its preparation and pharmaceutical compositions containing same
US4513008A (en) * 1982-07-30 1985-04-23 The Vinoxen Company, Inc. Virucidal compositions and therapy
US4841023A (en) * 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
WO1989003684A1 (en) * 1987-10-30 1989-05-05 Chugai Seiyaku Kabushiki Kaisha Anti-hiv agent

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CA 106: 131277a, 1987 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0524796A1 (en) * 1991-07-24 1993-01-27 Scotia Holdings Plc Use of essential fatty acids in the preparation of a medicament for the treatment of AIDS
WO1994001089A1 (en) * 1992-07-08 1994-01-20 Dianorm-Geräte G. Maierhofer Liposomes, method of preparing them and their use in the preparation of drugs
EP0733360A2 (en) * 1992-11-26 1996-09-25 Scotia Holdings Plc Use of a combination of arachidonic acid and dosohexaenoic acid in the preparation of e medicament for treating cell membrane abnormalities due to low C20 or C22 essential fatty acids
EP0733360A3 (en) * 1992-11-26 1996-10-02 Scotia Holdings Plc Use of a combination of arachidonic acid and dosohexaenoic acid in the preparation of e medicament for treating cell membrane abnormalities due to low C20 or C22 essential fatty acids
EP0767666A1 (en) * 1994-08-10 1997-04-16 The Rogosin Institute Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
EP0767666A4 (en) * 1994-08-10 1998-10-07 Rogosin Inst Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
WO2004050077A1 (en) * 2002-12-05 2004-06-17 Proyecto Empresarial Brudy, S.L. Use of docosahexanoic acid as active substance for the treatment of lipodystrophy
CN100355421C (en) * 2002-12-05 2007-12-19 布鲁迪企划有限公司 Use of docosahexanoic acid as active substance for the treatment of lipodystrophy
EA009711B1 (en) * 2002-12-05 2008-02-28 Проекто Эмпресариал Бруди, С.Л. Method for the treatment of lipodystrophy in a mammal
US8202906B2 (en) 2002-12-05 2012-06-19 Proyecto Empresarial Brudy, S.L. Use of docosahexanoic acid as active substance for the treatment of lipodystrophy

Similar Documents

Publication Publication Date Title
DE3926658C2 (en) Fatty acid composition
EP1838171B1 (en) Production and use of an antioxidant extract from crypthecodinium sp
DE4133694C2 (en) Use of an emulsion with polyunsaturated fatty acids for i.v. administration for the treatment of skin diseases
DE2747378A1 (en) LIPOSOME, METHOD OF MANUFACTURING AND MEDICINAL PRODUCTS CONTAINING THEM
EP0054769B1 (en) A process for the separation of oil and/or phosphatidylethanolamine from alcoholic phosphatidylcholin products containing them
DE69625616T3 (en) LIPID EMULSIONS WITH OPTIMIZED HYDROLYSIS AND THEIR USE
DE2834308A1 (en) METHOD FOR DETERMINING WATER FROM A COLLOIDAL LIPSOMEN DISPERSION
DE3409793A1 (en) LIQUID EMULSION FOR TRANSFUSION
DE2718797A1 (en) METHOD FOR OBTAINING OIL-BASED, HIGH-PURIFIED PHOSPHATIDYLCHOLINES
US6953849B2 (en) Process for the isolation of glycolipids
DE4017979A1 (en) Low cholesterol lipid mixt. used as medicine and for dietary nutrition - contains phosphatidyl choline, phosphatidyl ethanolamine, tri:glyceride(s), and arachidonic and docosa hexa:enoic acid
DE10361667A1 (en) Novel fat powder
EP0339382B1 (en) Process for deodorizing mixtures of fatty acid esters
EP0232501B1 (en) Pharmaceutical preparation for the treatment of lipid metabolism disorders (hyperlipoproteinemia)
DE2147327C3 (en) Process for obtaining purified, non-acylatable phosphatide
WO2001001797A1 (en) Oral form of administration
EP0273407A2 (en) Medicine for improving the specific properties of blood
DE60123603T2 (en) LIPID TO CHANGE THE DEFENSE SYSTEM
EP0604806A2 (en) Composition containing phospholipids
DE4000084A1 (en) INTRAVENOES APPLICABLE PHARMACEUTICAL PREPARATION OF ET18-OCH (DOWN ARROW) 3 (DOWN ARROW)
EP0240750B1 (en) Method for pasteurizing proteins of plasma and protein fractions of plasma
DE1173778C2 (en) PROCESS FOR PREPARING CLEAR, STABLE SOLUTIONS OF HIGH CONTENT CHOLINE PHOSPHORIC ACID DIGLYCERIDE STARS
DE1812204C3 (en) Process for the production of purified, non-acylatable phosphatide
DE1543937C3 (en) Use of modified cephalin-containing phosphatide mixtures as emulsifiers for O / W emulsions and processes for the production of such emulsifiers
DE4141842C2 (en) Use of N-acyl-phosphatidylethanolamines as antioxidants

Legal Events

Date Code Title Description
OP8 Request for examination as to paragraph 44 patent law
8131 Rejection